# Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

> **NCT03950050** · PHASE2 · COMPLETED · sponsor: **Shaare Zedek Medical Center** · enrollment: 40 (actual)

## Conditions studied

- Gaucher Disease, Type 1

## Interventions

- **DRUG:** Ambroxol

## Key facts

- **NCT ID:** NCT03950050
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950050, "Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03950050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*